期刊
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY
卷 14, 期 6, 页码 577-585出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/14787210.2016.1178065
关键词
Helicobacter pylori; therapy; bismuth; proton pump inhibitor; clarithromycin; amoxicillin; metronidazole; levofloxacin; tetracycline
资金
- Office of Research and Development Medical Research Service Department of Veterans Affairs, National Institute of Health Public Health Service [DK56338]
- BioGaia
Helicobacter pylori (H. Pylori) is a leading cause of gastroduodenal disease, including gastric cancer. H. pylori eradication therapies and their efficacy are summarized. A number of current treatment regimens will reliably yield > 90% or 95% cure rates with susceptible strains. None has proven to be superior. We show how to predict the efficacy of a regimen in any population provided one knows the prevalence of antibiotic resistance. As with other infectious diseases, therapy should always be susceptibility-based. Susceptibility testing should be demanded. We provide recommendations for empiric therapies when that is the only option and describe how to distinguish studies providing misinformation from those providing reliable and interpretable data. When treated as an infectious disease, high H. pylori cure rates are relatively simple to reliably achieve.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据